… Certain medical conditions may be associated with a slightly increased risk for false-positive
OraQuick® rapid HIV tests (eg, hepatitis A and B viruses, Epstein-Barr virus, multiparity, and …

These recommendations for human immunodeficiency virus (HIV) testing are intended for all
health-care providers in the public and private sectors, including those working in hospital …

… There is a lag period in most infections, and with B. burgdorferi, up to 3 weeks may be needed
from infection to B-cell production of pathogen-specific antibody in sufficient quantity to be …

The recent approval by the United States Food and Drug Administration of a rapid HIV self-test
marks a significant milestone in the evolution of HIV testing approaches. With nearly one …

… MD; BRANSON, BERNARD M. MD, AND; STEKETEE, RICHARD W. MD … Leynaert B,
Downs AM, de Vincenzi I. Heterosexual transmission of HIV: variability of infectivity …

Combination treatments with agents that inhibit protease and reverse transcriptase of human
immunodeficiency virus type 1 (HIV-1) decrease mortality and slow disease progression. …

Background: An estimated 1.2 million persons in the United States were living with human
immunodeficiency virus (HIV) infection in 2008. Improving survival of persons with HIV and …

… aged >1 year also recommend starting therapy on the basis of criteria other than stage, such
as a viral load >100,000 copies/mL or conditions that are important (eg, clinical category B […

… care and options for HCV treatment, take measures to limit HCV-associated disease progression
(eg, avoidance or reduction of alcohol intake, and vaccination against hepatitis A and B)…

This document updates recommendations for HIV testing by laboratories in the United States
and offers approaches for reporting test results to persons ordering HIV tests and to public …